AI assistant
PEAK PROCESSING LIMITED — Interim / Quarterly Report 2019
Feb 27, 2019
65568_rns_2019-02-27_92a89c93-d675-4748-b330-7c662ec5b57c.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
==> picture [80 x 51] intentionally omitted <==
ASX ANNOUNCEMENT
28[th] of February 2019
APPENDIX 4D
Results for Announcement to the Market
| Results for Announcement to the Market | |||
|---|---|---|---|
| Key Information | Half-year Ended | Half-year Ended | |
| 31 December 2018 | 31 December 2017 | ||
| $’000 | $’000 | % Change | |
| Revenue from ordinary activities | 174 | - | 100 |
| Loss from ordinary activities | (2,366) | (106) | 2,132 |
Dividends Paid and Proposed
There were no paid or proposed dividends for the half-year ended 31 December 2018.
Explanation of Key Information and Dividends
An explanation of the above figures is contained in the “Review of Operations” included within the attached directors’ report.
Net Tangible Assets per Share
| Net Tangible Assets per Share | ||
|---|---|---|
| Half-year Ended | Half-year Ended | |
| 31 December 2018 | 31 December 2017 | |
| $/Share | $/Share | |
| Net tangible assets per share | $0.11 | $261.33 |
Althea issued 203,310,000 shares in September 2018 as part of the capital raise. Therefore, the 31 December 2017 results are impacted by the limited numbers of shares on issue at that time.
Dividend Reinvestment Plans
The Group does not have any dividend reinvestment plans in operation.
Audit review
The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.
-ENDS-
About Althea
Althea Group Holdings Limited (ASX:AGH) is a patient-focused medicinal cannabis company that has all the required licenses and permits to import, cultivate, produce and supply medicinal cannabis in Australia.
Through a strategic partnership with cornerstone investor Aphria Inc., one of the largest cannabis companies listed in North America, Althea has become a leading supplier of medicinal cannabis in the Australian market.
Results for Announcement to the Market
Key Information Half-year Ended Half-year Ended 31 December 2018 31 December 2017 $’000 $’000 % Change
Althea’s focus on patient care underpins its business strategy. To this end, Althea has developed a mobile application and web-based platform to educate healthcare professionals on the benefits of medicinal cannabis and assist them in navigating the regulatory landscape. Althea is currently planning the construction of its own production facility and is in the process of expanding its product portfolio, patient numbers, and global footprint.
To learn more please visit: www.althea.com.au
Althea:
Josh Fegan, CEO & Managing Director 1300 70 20 20 | [email protected]
Investors:
PAC Partners Securities
03 8633 9834 | [email protected]
Media contacts:
The Capital Network Julia Maguire, Executive Director 0419 815 386 | [email protected]